Table 2. . Treatment-related adverse outcomes.

Variables	Cohort A (metformin) N = 21 (42%)	Cohort B (no metformin) N = 29 (58%)
Mean number of new metastatic site appeared while on therapy	1.7 ± 1.6	2.3 ± 2	p = 0.2
New skeletal metastasis on therapy	7 (33.3%)	7 (24.1%)	p = 0.4
New brain metastasis on therapy	1 (4.8%)	5 (17.2%)	p = 0.1
Fatigue	16 (76.2%)	28 (96.6%)	p = 0.02
Rash	1 (4.8%) (G 1)	1(3.4%) (G 1)	p = 0.8
Pneumonitis	1 (4.8%) (G 3)	5 (17.2%) (G 3–4)	p = 0.1
Acute kidney injury	0 (0%)	1 (3.4%) (G 3)	p = 0.2
Transaminitis	0 (0%)	2 (6.8%) (G 3–4)	p = 0.2
Colitis	3 (14.3%) (G 2–4)	3 (10.3%) (G 2–4)	p = 0.6
Hospitalization due to treatment	3 (14.3%)	7 (24.1%)	p = 0.3
IrAE (excluding fatigue)	7 (38.1%)	13 (44.8%)	p = 0.6
Prednisone required for IrAEs	6 (28.5%)	12 (41.3%)	p = 0.3

IrAE: Immune-related adverse event, G (Grade of IrAE)